Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca's COVID-19 Vaccine On Hold: A Reminder Product Development Is Never Straightforward

Phase III Trial Stopped A Week After Initiation

Executive Summary

AstraZeneca – one of the frontrunners in the race to develop a COVID-19 vaccine – has voluntarily put a hold on the Phase III trial due to an adverse event.

You may also be interested in...



After First COVID-19 Vaccine Approval, How Will Other Trials Maintain Placebo Control?

US FDA officials fear comparator arms would be unwieldy for ongoing trials as they consider alternative methods to measure efficacy if placebo controls can't be maintained for the studies of other candidate vaccines once a product is on the market.

COVID-19 Vaccination: Gaps In Pediatric Data Make Adult Uptake More Vital, Surgeon General Says

US lawmakers press the Surgeon General and NIH Director on how to instill vaccine confidence in an increasingly wary American public.

COVID-19 Vaccine Sponsors’ Pledge To Wait For Phase III Helps US FDA

The move reduces the pressure on the companies to rush development, but also relieves burden on the FDA to approve a candidate too soon.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID001014

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel